LabLogic announces strategic partnerships to advance Targeted Alpha Therapies
16 October 2024
At a glance
> LabLogic has committed to new projects focused on supporting innovative developments in Targeted Alpha Therapies.
> The first has been a Knowledge Transfer Partnership project initiated with the University of York to develop instruments for the Quality Control of alpha-emitting radionuclides.
> The second has been with the αccelerate.EU project, a 5-year project established to produce and supply 211At for clinical applications.
A commitment to advancing diagnostic and therapeutic capabilities
LabLogic is proud to announce two major partnerships that will drive forward the development of Targeted Alpha Therapies (TATs) for new innovative cancer treatments. These projects reflect our ongoing commitment to advancing both diagnostic and therapeutic capabilities in nuclear medicine through the development of new Quality Control instruments and methodologies.
TATs have the potential to transform patient care, offering new treatments for aggressive cancers such as triple-negative breast cancer, pancreatic cancer, and glioblastoma. However, the Quality Control checks for these therapies are still in the early stages of development compared to the more established standards for gamma and beta-emitting radionuclides.
Working with the University of York
KTP Associate Katie Staunton joins LabLogic’s R&D team from the University of Cambridge.
To address this, LabLogic has established a Knowledge Transfer Partnership (KTP) project with the University of York’s Nuclear Physics Group. Funded in part by Innovate UK, this collaboration aims to develop the next generation of QC instruments specifically for alpha-emitting radionuclides. The University of York’s Nuclear Physics Group brings extensive experience in sensor development and instrumentation, which will be crucial for modelling and optimising radiation detector performance for these new QC systems.
The partnership includes the appointment of Research & Development Physicist Katie Staunton, a PhD graduate of the University of Cambridge, who will play a key role in developing instruments that can accurately measure the radionuclidic identity, radionuclidic purity, and radiochemical purity of alpha-radiolabelled compounds.
Developing 211At for clinical applications
LabLogic has also joined the αccelerate.EU consortium, a five-year project dedicated to the production and clinical application of the alpha-emitting isotope 211At. Funded by the European Commission under the Innovative Health Initiative (IHI), it aims to establish a reliable production and distribution network for the promising isotope.
The αccelerate.EU consortium, led by the Brussels University Hospital - Jules Bordet Institute and IBA, includes 17 institutions from 9 countries, all working towards the goal of improving patient access to novel cancer treatments. At the centre of this initiative is the development of new therapeutic agents and the construction of a new cyclotron to support 211At production.
Interested in working with us?
LabLogic is always looking to partner with forward-thinking institutions in the field of nuclear medicine. If you’d like to speak to us more about alpha theranostics, click the button below to contact us.